# A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

> **NCT00036062** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 600 (—)

## Conditions studied

- Respiratory Distress Syndrome, Adult
- Acute Lung Injury

## Interventions

- **DRUG:** Sivelestat

## Key facts

- **NCT ID:** NCT00036062
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** —
- **Final completion:** 2002-12
- **Target enrollment:** 600 (—)
- **Last updated:** 2006-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00036062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00036062, "A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00036062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*